Abstract: The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthetase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthetase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.

Abstract: A voltage regulator having a multiple of main stages and at least one accelerated voltage regulator (AVR) bridge is provided. The main stages may respond to low frequency current transients and provide DC output voltage regulation. The AVR bridges are switched much faster than the main stages and respond to high frequency current transients without regulating the DC output voltage. The AVR bridge frequency response range can overlap with the main stage frequency response range, and the lowest frequency to which the AVR bridges respond may be set lower than the highest frequency to which the main stages respond.

Abstract: A microelectronic system may include a microelectronic component having electrically conductive elements exposed at a first surface thereof, a socket mounted to a first surface of the microelectronic component and including a substrate embedded therein, one or more microelectronic elements each having active semiconductor devices therein and each having element contacts exposed at a front face thereof, and a plurality of socket pins mounted to and extending above the substrate, the socket pins being ground shielded coaxial socket pins. The one or more microelectronic elements may be disposed at least partially within a recess defined within the socket. The socket may have a land grid array comprising top surfaces of the plurality of the socket pins or electrically conductive pads mounted to corresponding ones of the socket pins, and the element contacts of the one or more microelectronic elements may be pressed into contact with the land grid array.

Abstract: The present invention relates to an antibody binding specifically to an N-terminal region of lysyl-tRNA synthetase which is exposed on the cell membrane and a use thereof.

Abstract: The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

Abstract: The present invention relates to an anti-MRS monoclonal antibody and, more specifically, to an antibody or a fragment thereof characterized by specifically binding to a fragment represented by amino acid 861-900 of a human-derived methionyl-tRNA synthetase (MRS) protein set forth in SEQ ID NO:1, a method for producing the same, and a composition for diagnosing cancer comprising the same. The antibody or the fragment thereof of the present invention specifically binds to the human-derived MRS, and has no cross-reactivity with other proteins comprising the same ARS family. Therefore, as MRS detection is possible, the antibody or a fragment thereof can be effectively used for diagnosing MRS-related cancer.

Abstract: The present invention relates to a therapeutic agent for immune cell migration-caused disease and a method for screening the same and, more particularly, to a pharmaceutical composition comprising a KRS inhibitor (or expression or activity inhibitor) as an effective ingredient for preventing or treating an immune cell migration-related disease, a method for controlling the migration of immune cells by regulating a level of KRS in immune cells, a cell membrane site-specific moiety level of KRS or the migration of KRS to the cell membrane, and a method for screening a therapeutic agent for immune cell migration-caused disease, using KRS. According to the present invention, the migration of immune cells can be controlled by means of KRS, which can find very useful applications in the prevention, alleviation, and treatment of immune cell migration-related disease.

Abstract: The present invention relates to an antibody that specifically binds to the lysyl-tRNA synthase N-terminal domain exposed to the extracellular membrane, more specifically, it specifically binds to the lysyl-tRNA synthetase (KRS, Lysyl-tRNA synthetase)N-terminal domain exposed to the extracellular membrane having a specific CDR (complementarity determining region) sequence described herein, and relates to the use for the prevention, treatment or diagnosis of cancer, cancer metastasis, or diseases related to immune cell migration of a composition comprising an antibody or fragment thereof having high affinity and stability or the antibody and fragment thereof as an active ingredient. The method of the present invention can be usefully used to prepare an antibody having a higher affinity for the KRS N-terminus than a conventional antibody.

Abstract: The present invention relates to a method for diagnosing pancreatic cancer using methionyl-tRNA synthetase (MRS). When used as a pancreatic cancer marker, MRS has a significantly higher level of diagnostic accuracy than conventional pancreatic cancer markers such as CEA; thus, analyzing the expression status of methionyl-tRNA synthetase (MRS) in pancreatic cells has the effect of clearly determining the presence or absence of pancreatic cancer, and said effect is likewise exhibited even in the cells that have been determined to be atypical cells by a general staining technique, and thus can be very useful in the diagnosis of pancreatic cancer.

Abstract: The present invention relates to an anti-MRS monoclonal antibody and, more specifically, to an antibody or a fragment thereof characterized by specifically binding to a fragment represented by amino acid 861-900 of a human-derived methionyl-tRNA synthetase (MRS) protein set forth in SEQ ID NO:1, a method for producing the same, and a composition for diagnosing cancer comprising the same. The antibody or the fragment thereof of the present invention specifically binds to the human-derived MRS, and has no cross-reactivity with other proteins comprising the same ARS family. Therefore, as MRS detection is possible, the antibody or a fragment thereof can be effectively used for diagnosing MRS-related cancer.

Abstract: The present invention relates to a novel use of an antibody biding specifically to the N-terminus of lysyl-tRNA synthetase and, more particularly, to a pharmaceutical composition comprising an antibody biding specifically to an epitope including the sequence of SEQ ID NO: 117 in the N-terminal domain of lysyl-tRNA synthetase (KRS) or a functional fragment thereof as an effective ingredient for preventing and treating an immune cell migration-related disease. A KRS N-terminus-specific antibody provided by the present invention can regulate the migration of immune cells, thereby exhibiting very remarkable effects in the prevention, alleviation, and treatment of immune cell migration-related diseases.

Abstract: The present invention relates to a method for diagnosis of bile duct cancer, using methionyl-tRNA synthetase (MRS) in bile duct cells of a latent patient.

Abstract: The present invention relates to a therapeutic agent for immune cell migration-caused disease and a method for screening the same and, more particularly, to a pharmaceutical composition comprising a KRS inhibitor (or expression or activity inhibitor) as an effective ingredient for preventing or treating an immune cell migration-related disease, a method for controlling the migration of immune cells by regulating a level of KRS in immune cells, a cell membrane site-specific moiety level of KRS or the migration of KRS to the cell membrane, and a method for screening a therapeutic agent for immune cell migration-caused disease, using KRS. According to the present invention, the migration of immune cells can be controlled by means of KRS, which can find very useful applications in the prevention, alleviation, and treatment of immune cell migration-related disease.

Abstract: The present invention relates to an antibody binding specifically to an N-terminal region of lysyl-tRNA synthetase which is exposed on the cell membrane and a use thereof.

Abstract: Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient:

Abstract: A maleic acid derivative represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof: wherein, A is 5- to 7-membered phenyl having a substituent group, or heteroaryl or heterocycloalkyl containing at least one heteroatom selected from the group consisting of N, O, and S and having a substituent group, or 5- to 7-membered phenyl, heteroaryl, or heterocycloalkyl linked to C1-C5 straight- or branched-chain alkyl, wherein the substituent group is unsubstituted, halogen, OH, OR1, nitro, nitrile, NH2, NHR1, NR1R2 COOH, COOR1, CONH2, CONHR1, C1-C5 straight- or branched-chain alkyl, phenyl, heteroaryl, or 5- to 7-membered heterocycloalkyl, where R1 and R2 each are C1-C5 straight- or branched-chain alkyl, or phenyl or heteroaryl having a substituent group.

Abstract: Exemplary embodiments relate to a novel anticancer composition including a compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient: